HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA

Gut

Volumn 58, Issue 10, 2009, Pages 1399-1409

  Fritsche, P ^a   Seidler, B ^a   Schuler S ^a   Schnieke, A ^b   Gottlicher M ^c   Schmid, R M ^a   Saur, D ^a   Schneider, G ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; PROTEIN NOXA; TRANSCRIPTOME; VALPROIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; EPIGENETICS; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; GENE EXPRESSION PROFILING; GENE SILENCING; HISTONE DEACETYLASES; HUMANS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REPRESSOR PROTEINS; VALPROIC ACID;

EID: 70349309923     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.180711     Document Type: Article

References (46)

1. Schneider G, Siveke JT, Eckel F, et al. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005;128:1606-1625 (Pubitemid 40692555)
2. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-4811 (Pubitemid 44187627)
3. Hamacher R, Schmid RM, Saur D, et al. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer 2008;7:64.
4. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9:206-218 (Pubitemid 351301825)
5. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51. (Pubitemid 43054973)
6. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-5432
7. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784 (Pubitemid 44348499)
8. Donadelli M, Costanzo C, Faggioli L, et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinogenesis 2003;38:59-69. (Pubitemid 37255141)
9. Sato N, Ohta T, Kitagawa H, et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 2004;24:679-685
10. Ryu JK, Lee WJ, Lee KH, et al. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 2006;237:143-154
11. Ammerpohl O, Trauzold A, Schniewind B, et al. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 2007;96:73-81. (Pubitemid 46094642)
12. Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007;121:656-665 (Pubitemid 46986501)
13. Neureiter D, Zopf S, Leu T, et al. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 2007;42:103-116 (Pubitemid 46033053)
14. Ouaissi M, Cabral S, Tavares J, et al. Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. Cancer Biol Ther 2008;7:523-531 (Pubitemid 351847026)
15. Schneider G, Reichert M, Saur D, et al. HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2. Cell Prolif 2007;40:522-531 (Pubitemid 47063293)
16. Piacentini P, Donadelli M, Costanzo C, et al. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006;448:797-804. (Pubitemid 43824437)
17. Donadelli M, Costanzo C, Beghelli S, et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007;1773:1095-1106 (Pubitemid 46898677)
18. Reichert M, Saur D, Hamacher R, et al. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007;67:4149-4156 (Pubitemid 46815060)
19. Lallemand C, Blanchard B, Palmieri M, et al. Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via posttranslational modifications of IRF-1, IRF-3 and CREB. Oncogene 2007;26:328-338 (Pubitemid 46122823)
20. Seidler B, Schmidt A, Mayr U, et al. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci U S A 2008;105:10137-10142
21. Ishikawa M, Yoshida K, Yamashita Y, et al. Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. Cancer Sci 2005;96:387-393 (Pubitemid 41179739)
22. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 2001;20:6969-6978 (Pubitemid 34062289)
23. Kramer OH, Zhu P, Ostendorff HP, et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. Embo J 2003;22:3411-3420 (Pubitemid 36834871)
24. Shibue T, Takeda K, Oda E, et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 2003;17:2233-2238 (Pubitemid 37128638)
25. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 2003;302:1036-1038 (Pubitemid 37386194)
26. Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-463 (Pubitemid 38610247)
27. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404. (Pubitemid 40520691)
28. Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008;9:139-148
29. Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008;14:1669-1677
30. Zimmermann S, Kiefer F, Prudenziati M, et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 2007;67:9047-9054 (Pubitemid 47535889)
31. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-1802
32. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006;281:13548-13558 (Pubitemid 43855268)
33. Harms KL, Chen X. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 2007;67:3145-3152 (Pubitemid 46724851)
34. Bicaku E, Marchion DC, Schmitt ML, et al. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 2008;68:1513-1519 (Pubitemid 351346860)
35. Kaler P, Sasazuki T, Shirasawa S, et al. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Exp Cell Res 2008;314:1507-1518
36. Tsai SC, Valkov N, Yang WM, et al. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 2000;26:349-353 (Pubitemid 30824619)
37. Marchion DC, Bicaku E, Daud AI, et al. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 2005;4:1993-2000.
38. Marchion DC, Bicaku E, Turner JG, et al. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 2005;11:8467-8475 (Pubitemid 41746962)
39. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007;25:1979-1985 (Pubitemid 46972780)
40. Hacker G, Weber A. BH3-only proteins trigger cytochrome c release, but how? Arch Biochem Biophys 2007;462:150-155 (Pubitemid 46856314)
41. Hijikata M, Kato N, Sato T, et al. Molecular cloning and characterization of a cDNA for a novel phorbol-12-myristate-13-acetate-responsive gene that is highly expressed in an adult T-cell leukemia cell line. J Virol 1990;64:4632-4639 (Pubitemid 20329778)
42. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-1058 (Pubitemid 30324238)
43. Sasaki Y, Negishi H, Idogawa M, et al. Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models. Mol Cancer Ther 2008;7:779-787 (Pubitemid 351551031)
44. Inoue S, Riley J, Gant TW, et al. Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 2007;21:1773-1782 (Pubitemid 47086766)
45. Inoue S, Walewska R, Dyer MJ, et al. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia 2008;22:819-825 (Pubitemid 351552631)
46. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008;34:206-222